Isomab Ltd
Jay Modha is a CMC consultant with extensive experience in the biopharmaceutical industry. Jay currently works at Isomab Ltd as a CMC consultant and Imtol Inc as a CMC Lead. Jay is also the Founder & Director of Modha Biomedical Limited, specializing in CMC and IND-enabling studies for various biologics and ATMPs. Additionally, Jay has worked in roles such as CMC & Analytics SME at Primecore, CMC Technical Lead at Exacis Biotherapeutics, and Senior CMC Consultant at Enlivex Therapeutics. Jay holds a PhD in Parasite Immunology from the London School of Hygiene and Tropical Medicine, an MDiv. in Theology/Divinity from Reformed Theological Seminary, and a BSc. Hons. in Microbiology from the University of Surrey.
This person is not in any teams
Isomab Ltd
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.